Rapamycin combined with TGF-β converts human invariant NKT Cells into suppressive Foxp3 + regulatory cells

Journal of Immunology

Volumn 188, Issue 2, 2012, Pages 624-631

  Moreira Teixeira, Lúcia ^a,b   Resende, Mariana ^a,b   Devergne, Odile ^a   Herbeuval, Jean Philippe ^a   Hermine, Olivier ^a   Schneider, Elke ^a   Dy, Michel ^a   Cordeiro da Silva, Anabela ^b   Leite de Moraes, Maria C ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; RAPAMYCIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CD4+ T LYMPHOCYTE; CELL INTERACTION; CELL STIMULATION; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFORMATION; NATURAL KILLER T CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; TRANSCRIPTION REGULATION; UPREGULATION;

CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; FETAL BLOOD; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTES, MONONUCLEAR; NATURAL KILLER T-CELLS; SIROLIMUS; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 84855999082     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1102281     Document Type: Article

References (53)

1. Kronenberg, M. 2005. Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol. 23: 877-900. (Pubitemid 40563188)
2. Bendelac, A., P. B. Savage, and L. Teyton. 2007. The biology of NKT cells. Annu. Rev. Immunol. 25: 297-336. (Pubitemid 46697911)
3. + NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103: 383-389.
4. Cerundolo, V., J. D. Silk, S. H. Masri, and M. Salio. 2009. Harnessing invariant NKT cells in vaccination strategies. Nat. Rev. Immunol. 9: 28-38.
5. Exley, M., S. Porcelli, M. Furman, J. Garcia, and S. Balk. 1998. CD161 (NKRP1A) costimulation of CD1d-dependent activation of human T cells expressing invariant Vα24JαQ T cell receptor α chains. J. Exp. Med. 188: 867-876. (Pubitemid 28433413)
6. Gumperz, J. E., S. Miyake, T. Yamamura, and M. B. Brenner. 2002. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med. 195: 625-636. (Pubitemid 34461507)
7. α14 NKT cells by glycosylceramides. Science 278: 1626-1629.
8. Mattner, J., K. L. Debord, N. Ismail, R. D. Goff, C. Cantu, III, D. Zhou, P. Saint- Mezard, V. Wang, Y. Gao, N. Yin, et al. 2005. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434: 525-529. (Pubitemid 40477062)
9. Kinjo, Y., E. Tupin, D. Wu, M. Fujio, R. Garcia-Navarro, M. R. Benhnia, D. M. Zajonc, G. Ben-Menachem, G. D. Ainge, G. F. Painter, et al. 2006. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat. Immunol. 7: 978-986. (Pubitemid 44263912)
10. neg iNKT cell population involved in airway neutrophilia. J. Exp. Med. 204: 995-1001.
11. Michel, M. L., D. Mendes-da-Cruz, A. C. Keller, M. Lochner, E. Schneider, M. Dy, G. Eberl, and M. C. Leite-de-Moraes. 2008. Critical role of ROR-γt in a new thymic pathway leading to IL-17-producing invariant NKT cell differentiation. Proc. Natl. Acad. Sci. USA 105: 19845-19850.
12. Moreira-Teixeira, L., M. Resende, M. Coffre, O. Devergne, J. P. Herbeuval, O. Hermine, E. Schneider, L. Rogge, F. M. Ruemmele, M. Dy, et al. 2011. Proinflammatory environment dictates the IL-17-producing capacity of human invariant NKT cells. J. Immunol. 186: 5758-5765.
13. Matsuda, J. L., T. Mallevaey, J. Scott-Browne, and L. Gapin. 2008. CD1drestricted iNKT cells, the "Swiss-Army knife" of the immune system. Curr. Opin. Immunol. 20: 358-368.
14. Smyth, M. J., K. Y. Thia, S. E. Street, E. Cretney, J. A. Trapani, M. Taniguchi, T. Kawano, S. B. Pelikan, N. Y. Crowe, and D. I. Godfrey. 2000. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191: 661-668.
15. Lisbonne, M., S. Diem, A. de Castro Keller, J. Lefort, L. M. Araujo, P. Hachem, J. M. Fourneau, S. Sidobre, M. Kronenberg, M. Taniguchi, et al. 2003. Cutting edge: invariant Vα14 NKT cells are required for allergen-induced airway inflammation and hyperreactivity in an experimental asthma model. J. Immunol. 171: 1637-1641. (Pubitemid 36966444)
16. Akbari, O., P. Stock, E. Meyer, M. Kronenberg, S. Sidobre, T. Nakayama, M. Taniguchi, M. J. Grusby, R. H. DeKruyff, and D. T. Umetsu. 2003. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergeninduced airway hyperreactivity. Nat. Med. 9: 582-588. (Pubitemid 36597105)
17. Hachem, P., M. Lisbonne, M. L. Michel, S. Diem, S. Roongapinun, J. Lefort, G. Marchal, A. Herbelin, P. W. Askenase, M. Dy, and M. C. Leite-de-Moraes. 2005. α-Galactosylceramide-induced iNKT cells suppress experimental allergic asthma in sensitized mice: role of IFN-γ. Eur. J. Immunol. 35: 2793-2802. (Pubitemid 41555076)
18. Wu, L., and L. Van Kaer. 2009. Natural killer T cells and autoimmune disease. Curr. Mol. Med. 9: 4-14.
19. Lehuen, A., J. Diana, P. Zaccone, and A. Cooke. 2010. Immune cell crosstalk in type 1 diabetes. Nat. Rev. Immunol. 10: 501-513.
20. Pichavant, M., S. Goya, E. H. Meyer, R. A. Johnston, H. Y. Kim, P. Matangkasombut,M. Zhu, Y. Iwakura, P. B. Savage, R.H. DeKruyff, et al. 2008. Ozone exposure in a mouse model induces airway hyperreactivity that requires the presence of natural killer T cells and IL-17. J. Exp. Med. 205: 385-393. (Pubitemid 351281604)
21. + regulatory T cells? Eur. J. Immunol. 35: 1193-1200.
22. + invariant NKT cells induced by TGF-β. J. Immunol. 185: 2157-2163.
23. Engelmann, P., K. Farkas, J. Kis, G. Richman, Z. Zhang, C. W. Liew, M. Borowiec, M. A. Niewczas, H. Jalahej, and T. Orbán. 2011. Characterization of human invariant natural killer T cells expressing FoxP3. Int. Immunol. 23: 473-484.
24. +FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-β dependent but does not confer a regulatory phenotype. Blood 110: 2983-2990.
25. Gavin, M. A., T. R. Torgerson, E. Houston, P. DeRoos, W. Y. Ho, A. Stray- Pedersen, E. L. Ocheltree, P. D. Greenberg, H. D. Ochs, and A. Y. Rudensky. 2006. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc. Natl. Acad. Sci. USA 103: 6659-6664.
26. +NKT lymphocytes are activated memory cells. Eur. J. Immunol. 30: 1544-1550.
27. -subsets of Vα24-invariant natural killer T cells in humans. Blood 104: 4150-4156.
28. Sakaguchi, S., T. Yamaguchi, T. Nomura, and M. Ono. 2008. Regulatory T cells and immune tolerance. Cell 133: 775-787. (Pubitemid 351707693)
29. Lee, P. T., K. Benlagha, L. Teyton, and A. Bendelac. 2002. Distinct functional lineages of human Vα24 natural killer T cells. J. Exp. Med. 195: 637-641. (Pubitemid 34461508)
30. Li, M. O., and R. A. Flavell. 2008. TGF-β: a master of all T cell trades. Cell 134: 392-404.
31. + regulatory T cells in humans. Proc. Natl. Acad. Sci. USA 106: 4793-4798.
32. Ziegler, S. F. 2006. FOXP3: of mice and men. Annu. Rev. Immunol. 24: 209-226.
33. Hori, S., T. Nomura, and S. Sakaguchi. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061. (Pubitemid 36222930)
34. + regulatory T cells. Nat. Immunol. 4: 330-336.
35. + T cells. J. Immunol. 177: 944-949.
36. + T cells expressing the FoxP3 transcription factor. Immunity 30: 899-911.
37. Williams, L. M., and A. Y. Rudensky. 2007. Maintenance of the Foxp3- dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat. Immunol. 8: 277-284. (Pubitemid 46745377)
38. Tone, Y., K. Furuuchi, Y. Kojima, M. L. Tykocinski, M. I. Greene, and M. Tone. 2008. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat. Immunol. 9: 194-202.
39. Song, K., H.Wang, T. L. Krebs, and D. Danielpour. 2006. Novel roles of Akt and mTOR in suppressing TGF-β/ALK5-mediated Smad3 activation. EMBO J. 25: 58-69. (Pubitemid 43077295)
40. + regulatory T cells. Blood 105: 4743-4748.
41. + regulatory T cells cultured with rapamycin. J. Immunol. 178: 320-329.
42. Strauss, L., M. Czystowska, M. Szajnik, M. Mandapathil, and T. L. Whiteside. 2009. Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. PLoS ONE 4: e5994.
43. Bettelli, E., Y. Carrier, W. Gao, T. Korn, T. B. Strom, M. Oukka, H. L. Weiner, and V. K. Kuchroo. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235-238.
44. Beriou, G., C. M. Costantino, C.W. Ashley, L. Yang, V. K. Kuchroo, C. Baecher- Allan, and D. A. Hafler. 2009. IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood 113: 4240-4249.
45. Zhou, L., J. E. Lopes, M. M. Chong, I. I. Ivanov, R. Min, G. D. Victora, Y. Shen, J. Du, Y. P. Rubtsov, A. Y. Rudensky, et al. 2008. TGF-β-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORgt function. Nature 453: 236-240. (Pubitemid 351667978)
46. Miyara, M., K. Wing, and S. Sakaguchi. 2009. Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion. J. Allergy Clin. Immunol. 123: 749-755.
47. Brigl, M., R. V. Tatituri, G. F. Watts, V. Bhowruth, E. A. Leadbetter, N. Barton, N. R. Cohen, F. F. Hsu, G. S. Besra, and M. B. Brenner. 2011. Innate and cytokine-driven signals, rather than microbial antigens, dominate in natural killer T cell activation during microbial infection. J. Exp. Med. 208: 1163-1177.
48. -subset dynamics and correlates with remission state. J. Immunol. 186: 4490-4499.
49. Wermeling, F., S. M. Lind, E. D. Jordö, S. L. Cardell, and M. C. Karlsson. 2010. Invariant NKT cells limit activation of autoreactive CD1d-positive B cells. J. Exp. Med. 207: 943-952.
50. + T regulatory cells that protects against graft-versus-host disease. Blood 113: 4458-4467.
51. Leveson-Gower, D. B., J. A. Olson, E. I. Sega, R. H. Luong, J. Baker, R. Zeiser, and R. S. Negrin. 2011. Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanism. Blood 117: 3220-3229.
52. Morris, E. S., K. P.MacDonald, R. D. Kuns, H. M. Morris, T. Banovic, A. L. Don, V. Rowe, Y. A. Wilson, N. C. Raffelt, C. R. Engwerda, et al. 2009. Induction of natural killer T cell-dependent alloreactivity by administration of granulocyte colony-stimulating factor after bone marrow transplantation. Nat. Med. 15: 436-441.
53. Novak, J., L. Beaudoin, T. Griseri, and A. Lehuen. 2005. Inhibition of T cell differentiation into effectors by NKT cells requires cell contacts. J. Immunol. 174: 1954-1961. (Pubitemid 40223936)